Showing results (121-130 of 297) with videos related to

Sort By:
Pageof 30
Journal of the American Society of Nephrology : JASN|February 1, 2008
Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritisJuliane Scholz, Veronika Lukacs-Kornek, Daniel R Engel, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 TrialsTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International|July 30, 2010
Differential activation of memory-relevant brain regions during a dialysis cycleSilke Lux, Shahram Mirzazade, Bojana Kuzmanovic, et al.
BMC Nephrology|November 21, 2018
Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)Judith Isabel Schimpf, Till Klein, Christina Fitzner, et al.
Kidney360|December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial ResultsHong Zhang, Richard Lafayette, Bei Wang, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in JapanTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|November 9, 2020
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyRichard A Lafayette, Brad H Rovin, Heather N Reich, et al.
Advances in Therapy|February 7, 2023
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Frank Dellanna, Jose Portoles, et al.
Kidney International Reports|May 16, 2022
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy VolunteersMohit Mathur, Jonathan Barratt, Yusuke Suzuki, et al.
Pageof 30